Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines

Ali Azizi*, Gathoni Kamuyu, Deborah Ogbeni, Philipa Levesque-Damphousse, Daniel Knott, Luc Gagnon, Steven Phay-Tran, Bethan Hussey, Pamela Proud, Sue Charlton, Carolyn Clark, Valentina Bernasconi

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract

To date, thousands of SARS-CoV-2 samples from many vaccine developers have been tested within the CEPI-Centralized Laboratory Network. To convert data from each clinical assay to international standard units, the WHO international standard and the CEPI standard generated by the Medicines and Healthcare products Regulatory Agency were run in multiple facilities to determine the conversion factor for each assay. Reporting results in international units advances global understanding of SARS-CoV-2 immunity and vaccine efficacy, enhancing the quality, reliability, and utility of clinical assay data.

Original languageEnglish
Article number2344249
JournalHuman Vaccines and Immunotherapeutics
Volume20
Issue number1
DOIs
Publication statusPublished - 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.

Keywords

  • CEPI-CLN
  • SARS-CoV-2 pandemic
  • immunological assays
  • standardization
  • vaccine efficacy

Fingerprint

Dive into the research topics of 'Driving consistency: CEPI-Centralized Laboratory Network’s conversion factor initiative for SARS-CoV-2 clinical assays used for efficacy assessment of COVID vaccines'. Together they form a unique fingerprint.

Cite this